Johannesburg, 13 August 20: With food security increasingly under the microscope in the wake of the global COVID-19 pandemic and increasing financial pressure on the dairy sector, global animal health company, Zoetis, has launched Clarifide® Plus to predict key cow and calf wellness traits in South Africa’s dairy cattle.
According to the technical manager for the Ruminants Division at Zoetis South Africa, Dr. Chantelle Erwee, genomic testing will assist dairy farmers in identifying specific traits in dairy cattle to predict which animals are more resilient to certain costly diseases as well as those with higher potential for important traits such as milk production, fertility, and productive life.
The aim of the Clarifide® Plus genomic test is to help dairy farmers to build a healthier herd by testing heifers as early as possible in their lifetime. This will help to avoid unnecessary costs incurred by raising heifers that end up leaving the herd prematurely. At the same time, farmers will be able to improve breeding strategies and selection decisions.
The number of dairy farms in South Africa has dropped by 65 % between January 2009 and August 2019. However, the good news is that despite major changes in the industry, milk production increased by 31 % between 2009 and 2018 and milk production per producer rose by 273 %. Ultimately, reliable information provided by genomic testing will enable farmers to fine-tune their management, selection, and breeding decisions with confidence.
Clarifide® Plus is the only genomic test that allows producers to rank animals with the Dairy Wellness Profit Index® (DWP$®) which is based on traits that affect health, performance, and the lifetime profit of cows and calves. DWP$ describes more genetic variation in profitability allowing for faster progress towards greater profitability.
Zoetis teamed up with an agricultural banking and consulting institution to identify dairy operating measures that correlate with the financial health of contemporary dairy farms. From this, six key financial drivers of Net Farm Income were identified – net herd replacement costs, pregnancy rates, heifer survival, energy corrected milk, somatic cell count, and death loss in cows. ²
Clarifide® Plus enhances the ability to improve the outcomes of these financial drivers by improving the ability to genetically select key performance and wellness-related traits.
“Cow and calf wellness genomic predictions were developed because of the commitment by Zoetis to the continuum of care for dairy cattle. Zoetis strives to improve dairy wellness and understand genetic factors impacting resistance to common diseases in dairy cattle,” says Dr. Erwee.
Profitability is enhanced when a dairy has the advantage of mature cows that are productive and healthy for multiple lactations. To reach their full potential and longevity, animals need to remain healthy from birth until calving and then cows must stay healthy and be reproductively sound, in addition to producing milk.
Dr. Erwee says that utilising genomic testing like Clarifide® Plus also assists farmers and veterinarians involved in technologies such as embryo transfer to make smart decisions when it comes to selecting females as recipients or donors and indirectly guides them on sire selection.
- The South African Dairy situation, MPO, November 2019
- Clarifide® Plus enhances Key financial drivers impacting net farm income, January 2018
A leading multi-national animal health company, Zoetis builds on more than 65 years of experience in animal health to research, develop, manufacture and commercialize medicines, vaccines, and diagnostic products. Zoetis understands the deep connection between people and their pet and provides veterinarians with the resources needed to provide the highest quality of care and support, help improve the quality and extend the life of cats, dogs, and horses and make it easier for owners to contribute towards the health and wellness of their companion animals. Zoetis produces vaccines, anti-infectives, parasiticides, dermatology products, animal health diagnostic, and other pharmaceuticals.